NewTimeSpace News: Sigenergy Technology announced on 30 July that the Group expects its revenue for the first half of 2026 to range from approximately RMB 9.5 billion to RMB 10 billion, representing a year-on-year growth of roughly 240% to 270%; its net profit is projected at about RMB 2.35 billion to RMB 2.45 billion, up 190% to 210% year-on-year.
NewTimeSpace News: HSBC Holdings plc announced on 31 July that HSBC Bank Australia, its indirect wholly-owned subsidiary, agreed to sell its Australian residential and personal loan portfolio to an entity affiliated with a Blackstone-managed fund at an aggregate consideration of approximately A$36 billion (around US$25 billion).
NewTimeSpace News: Shanghai TopNC announced that its board, authorized by shareholders at the 29 July 2026 EGM to repurchase up to 38.13 million H shares (10% of issued H shares), proposes to conduct on-market buybacks capped at HK$300 million using internal resources rather than IPO proceeds; the board views this as a demonstration of confidence in the company's business outlook, with repurchased shares to be cancelled or held in treasury while maintaining the required public float.
July 30, 2026, DEEPEXI TECH(01384.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 283.99 million, increased by 114.97% YoY
NewTimeSpace News: Shaw Brothers provided a monthly update on its potential extreme transaction to acquire the entire issued share capital of CMC MOON HOLDINGS LIMITED, stating that due diligence and circular preparation are ongoing and PRC filing and approval procedures are being fulfilled, though no conditions have been satisfied as of the announcement date; the board reminded shareholders that the acquisition remains subject to multiple conditions including independent shareholder approval and an extreme transaction determination, and may not proceed.
NewTimeSpace News: Sunshine Lake Pharma announced NMPA approval for its self-developed Insulin Degludec Injection in two specifications, expanding its domestic insulin portfolio to six products spanning second- to fourth-generation therapies; the group also disclosed that its insulin aspart/degludec dual formulation is under marketing review and HEC-151 has entered Phase I trials, following its insulin glargine becoming the first Chinese-developed product of its kind approved by the FDA in April 2026.
By the close of trading on Jul 30, 2026, HAIZHI TECH GP(02706.HK) saw a loss of 19.09% in its share price, closing at HKD 21.44. During the session, it reached an intraday high of HKD 26.5
By the close of trading on Jul 30, 2026, CFMEE(09630.HK) saw a loss of 17.39% in its share price, closing at HKD 229. During the session, it reached an intraday high of HKD 276.2 and touched an intraday low of HKD 228.
By the close of trading on Jul 30, 2026, ANKER(00668.HK) saw a gain of 10.25% in its share price, closing at HKD 118.3. During the session, it reached an intraday high of HKD 120.8 and touched an intraday low of HKD 104.7.
By the close of trading on Jul 30, 2026, Z.AI(02513.HK) saw a loss of 16.55% in its share price, closing at HKD 862. During the session, it reached an intraday high of HKD 1048 and touched an intraday low of HKD 840.
FOREST CABIN(02657.HK) will spend HKD 15.24 million to repurchase 284.2 thousand shares on Jul 30, 2026 .
July 30, 2026, PLOVER BAY TECH(01523.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at USD 74.6 million, increased by 18.51% YoY
NewTimeSpace News: Sirnaomics Ltd. (02257.HK) announced that the first patient has been successfully dosed in a Phase 2 multicenter clinical trial evaluating STP705 for medical aesthetics. The trial aims to systematically assess the clinical efficacy of STP705 in achieving targeted subcutaneous fat reduction through local administration, leveraging the Group's proprietary PNP oligonucleotide delivery platform, which enables site-specific gene regulation to drive controlled adipocyte clearance.
NewTimeSpace News: CANbridge Pharmaceuticals Inc. (01228.HK) announced on July 30 that GORYNIN®, a treatment for Gaucher disease, has commenced registration and commercialization preparations in the North African market. GORYNIN® is the Company's first self-developed enzyme replacement therapy, approved in China in May 2025. The Company stated it will pursue a global market strategy, though it has yet to generate any sales revenue from North Africa, where the registration process remains subject to regulatory approval.
NewTimeSpace News: Shanghai Henlius Biotech, Inc. (02696.HK) announced that the first patient has been dosed in a Phase 1 clinical study in China for its self-developed HLX3902 Injection, a STEAP1×CD3×CD28 trispecific antibody, for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and other advanced solid tumors. To date, no trispecific antibody of the same target class has been approved for marketing globally.
NewTimeSpace News: MGM China Holdings Limited (02282.HK) announced that Executive Director Ms. Liu Zhenni will be appointed as Chief Financial Officer with effect from August 1, 2026.
